Les membres de la FHU GOAL coordonnent et conduisent des essais cliniques de phases 1, 2 et 3, ayant pour thématiques la physiopathologie, l'exploration et le traitement :
-
des leucémies aigües myéloblastiques ou lymphoblastiques du sujet jeune ou plus âgé en première poussée évolutive ou en rechute
-
des affections immédiatement préleucémiques telles que les syndromes myéloprolifératifs chroniques et à un moindre degré les syndromes myélodysplasiques
-
des travaux communs sur les allogreffes, conditionnements ou maintenance
​Les projets portés par la FHU GOAL incluent également des études observationnelles, la constitution de bases de données cliniques et biologiques.
RECHERCHE CLINIQUE ET TRANSLATIONNELLE
Ces protocoles sont promus au sein de l'inter-région Grand-Ouest :
APHYPAP : Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms
NCT03808805 - IP: Pr JC Ianotto, CHU Brest
AVAJAK : Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
NCT05198960 - IP: Pr JC Ianotto, CHU Brest
BIG-1 : Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR
NCT02416388 - IP: Pr M Hunault, CHU Angers
BIOPREDICTOR : Identification of Factors Associated With Treatment Response in Patients With Polycythemia Vera, Essential Thrombocythemia, and Pre-myelofibrosis.
NCT05440838 - IP: Dr D Luque Paz et Dr C Orvain, CHU Angers
BIOSCORE SMP : Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms.
NCT03869476 - IP: Dr D Luque Paz et Dr C Orvain, CHU Angers
CALRSUIVI : Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndrome
NCT04942080 - IP: Dr L Cottin, CHU Angers
FLAMVAL : Validation Study of a New Cytokine-based Dynamic Stratification Based on FLt3 Ligand Plasma Concentration Kinetic Profile and IL-6 Concentration During Induction of Acute Myeloid Leukemia
NCT04641910 - IP: Dr P Peterlin, CHU Nantes
ILDA : Injection of Lymphocytes From Haplo-identical Donor Following Chemotherapy in Patients With High-risk Acute Myeloblastic Leukemia Not Eligible for an Allogeneic Hematopoietic Stem Cell Transplantation
NCT04886206 - IP: Dr T Guillaume, CHU Nantes
KINHémo : Physical Fitness Impact of Early Physiotherapy Intervention With a Standardized Exercise Therapy Program in Adult Patients Receiving Intensive Induction Chemotherapy for Treatment of Acute Leukemia During Extended Hospitalization.
NCT04899882 - IP: M Lubi Leon, CHU Angers
MOLAM : Outcome of Patients With CBF and/or NPM1-mutated AML in First Molecular Relapse.
NCT04931992 - IP: Dr C Orvain, CHU Angers
SMD-RMB22 : Haploinsufficiency of the RBM22 and SLU7 Genes in Del(5q) Myelodysplastic Syndromes
NCT04701229 - IP: Dr MB Troadec, CHU Brest
SYTHROM Cohort, Myeloproliferative Neoplasia With Normal CBC and Thrombotic Complications
NCT04539678 - IP: Dr Y Le Bris, CHU Nantes
TOCILAM : Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML)
NCT04547062 - IP: Dr P Peterlin, CHU Nantes